Teri  Loxam net worth and biography

Teri Loxam Biography and Net Worth

Director of Vaxcyte

Ms. Loxam is currently the Chief Financial Officer of Compass Pathways, a company dedicated to accelerating patient access to evidence-based innovation in mental health. With over 25 years of diverse experience across investor relations, strategy, communications and finance, Ms. Loxam was previously the Chief Financial Officer of Gameto where she played a pivotal role in negotiating multiple licensing agreements and helping to develop the regulatory and commercial strategy for their lead product. Ms. Loxam also served as Chief Financial Officer and Chief Operating Officer of Kira Pharmaceuticals, where she advanced their lead asset into Phase 2 and grew the company’s pipeline. As Chief Financial Officer of SQZ Biotech, Ms. Loxam led the company to a successful IPO and raised over $200 million in the first 18 months in her role. Before joining SQZ Biotechnologies, Ms. Loxam served as Senior Vice President of Investor Relations and Global Communications at Merck where she helped establish the company’s leadership in immuno-oncology with the investment community along with leading internal and external communications efforts globally, which included Merck’s portfolio of therapeutics and vaccines. Ms. Loxam also spent over a decade at Bristol-Myers Squibb in a variety of roles of increasing responsibility across strategy, treasury and investor relations and served as Vice President of Investor Relations at IMAX, an entertainment technology company. Ms. Loxam serves as a member of the board of directors of Vaxcyte, Inc., since September 2021, and Cardiol Therapeutics. She has a BS in Biology from the University of Victoria, BC Canada and an MBA from the University of California, Irvine.

What is Teri Loxam's net worth?

The estimated net worth of Teri Loxam is at least $515,882.50 as of January 15th, 2025. Ms. Loxam owns 7,175 shares of Vaxcyte stock worth more than $515,883 as of March 25th. This net worth evaluation does not reflect any other assets that Ms. Loxam may own. Learn More about Teri Loxam's net worth.

How do I contact Teri Loxam?

The corporate mailing address for Ms. Loxam and other Vaxcyte executives is 353 HATCH DRIVE, FOSTER CITY CA, 94404. Vaxcyte can also be reached via phone at 650-837-0111 and via email at investors@vaxcyte.com. Learn More on Teri Loxam's contact information.

Has Teri Loxam been buying or selling shares of Vaxcyte?

In the last ninety days, Teri Loxam has sold $531,937.50 of Vaxcyte stock. Most recently, Teri Loxam sold 6,250 shares of the business's stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $85.11, for a transaction totalling $531,937.50. Following the completion of the sale, the director now directly owns 7,175 shares of the company's stock, valued at $610,664.25. Learn More on Teri Loxam's trading history.

Who are Vaxcyte's active insiders?

Vaxcyte's insider roster includes Elvia Cowan (SVP), Mikhail Eydelman (SVP), Jeff Fairman (VP), Halley Gilbert (Director), Andrew Guggenhime (CFO), Teri Loxam (Director), Heath Lukatch (Director), Grant Pickering (CEO), Paul Sauer (SVP), James Wassil (COO), Jim Wassil (COO), and Jane Wright-Mitchell (General Counsel). Learn More on Vaxcyte's active insiders.

Are insiders buying or selling shares of Vaxcyte?

In the last year, insiders at the sold shares 38 times. They sold a total of 343,846 shares worth more than $30,339,268.37. The most recent insider tranaction occured on March, 3rd when COO Jim Wassil sold 8,000 shares worth more than $586,160.00. Insiders at Vaxcyte own 3.1% of the company. Learn More about insider trades at Vaxcyte.

Information on this page was last updated on 3/3/2025.

Teri Loxam Insider Trading History at Vaxcyte

See Full Table

Teri Loxam Buying and Selling Activity at Vaxcyte

This chart shows Teri Loxam's buying and selling at Vaxcyte by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$532ksoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$400k-$200k$0$200k$400kTotal Insider BuyingTotal Insider Selling

Vaxcyte Company Overview

Vaxcyte logo
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Read More

Today's Range

Now: $71.90
Low: $71.13
High: $73.76

50 Day Range

MA: $81.14
Low: $68.89
High: $92.13

2 Week Range

Now: $71.90
Low: $58.10
High: $121.06

Volume

727,085 shs

Average Volume

936,328 shs

Market Capitalization

$9.26 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.02